63 results about "Drug accumulation" patented technology

The invention relates to an active oxygen responsive triptolide prodrug immunoregulation hydrogel preparation as well as a preparation method and application thereof. Triptolide is coupled with an active oxygen responsive group to synthesize a triptolide derivative; then, the triptolide derivative is coupled with polypeptide, and a polypeptide-reactive oxygen responsive group-triptolide conjugate is obtained; then dissolving the polypeptide-active oxygen responsive group-triptolide conjugate in a solvent, standing, and carrying out self-assembly to obtain a triptolide prodrug nanofiber solution; finally, an immunomodulator is added into the triptolide prodrug nanofiber solution for incubation, and the active oxygen responsive triptolide prodrug immunoregulation hydrogel preparation is obtained. The hydrogel preparation disclosed by the invention can responsively release the medicine triptolide and the immunomodulator at the focus part of rheumatoid arthritis, so that the medicine accumulation of non-target organs is reduced, the safety and effectiveness of treatment are improved, and the progress of diseases is effectively controlled.

Disclosed in the present invention are a benzodiazepine compound, a pharmaceutical composition and the use thereof. Specifically provided is a compound represented by formula I, or a stereoisomer thereof, a deuterated compound thereof, or a pharmaceutically acceptable salt thereof. The compound provided in the present invention has one or more of the following advantageous effects: (1) the compound of the present invention exhibits good intravenous sedative and anesthetic effects; (2) the compound of the present invention exhibits low drug accumulation and a good tolerance; and (3) the compound of the present invention achieves an anesthetic effect with faster recovery.

The invention discloses allicin oleogel as well as a preparation method and application thereof, and belongs to the technical field of medicines. The allicin oleogel is prepared from the following raw materials: allicin, an oil phase, a gelator and a surfactant, the gelator comprises beeswax and / or fruit wax; the surfactant comprises one or more of caprylic / capric polyethylene glycol glyceride, Tween 20 and polyglycerol fatty acid ester. The gel factor forms oil gel through crystal self-assembly, allicin is solidified and intercepted in the oil gel, the gel factor is optimized, and a surfactant is used in a matched manner, so that a release behavior similar to that of a mixed solution of free allicin and an oil phase can be obtained, and the transdermal release rate is improved. The allicin oil gel can effectively entrap allicin, cover the peculiar smell of the allicin and improve the stability of the allicin, and through abdominal transdermal administration, the medicine accumulation amount in subcutaneous adipose tissues is remarkably increased, and the treatment effect on obesity and complications thereof can be improved.

The invention discloses a universal mononuclear / macrophage delivery system for enhancing fibrosis part drug accumulation and application, and the universal mononuclear / macrophage delivery system comprises the following steps: (1) preparation of a carrier: adding a low-oxygen response element HRE fused MMP14 plasmid into an aqueous phase solution, then preparing an RMR-LNP suspension from the aqueous phase solution and an oil phase solution by adopting a microfluidic technology, and purifying to obtain the carrier; then, DSPE-PEG2000-TriArg is added into the purified system, incubation is carried out, and RMR-L-TriArg is obtained; and (2) transfecting the mononuclear / macrophage: co-incubating the RMR-L-TriArg and the mononuclear / macrophage, and then transfecting to obtain the mononuclear / macrophage delivery system for enhancing the drug accumulation at the fibrosis part. By constructing MMP14 high-expression macrophages, delivery to the hepatic fibrosis site can be increased, accumulation of drugs is increased, and the treatment effect is enhanced.

Provided is use of a KIF18A inhibitor in preparing a medicament for treating ovarian cancer disease. Pharmacological studies have demonstrated that compounds 1-3 can inhibit the growth of ovarian cancer heterogeneous tumors, and a high dose of the compounds can cause tumor regression in mice. Compared with AMG650, a lower drug exposure of compounds 1-3 reduces the potential drug accumulation toxicity and possesses a significant therapeutic effect on ovarian cancer with good safety.

The present invention discloses a near-infrared photosensitizer-based nanotherapeutic agent, its preparation method, and application. The near-infrared photosensitizer-based nanotherapeutic agent comprises a protein and a near-infrared prodrug bound to a hydrophobic cavity of the protein. The near-infrared prodrug comprises a near-infrared photosensitizer connected to a cupric sulfide bond and a chemotherapy drug bound to the near-infrared photosensitizer connected to the cupric sulfide bond via a thioketone bond. The near-infrared photosensitizer-based nanotherapeutic agent provided by the present invention significantly improves the solubility and bioavailability of the chemotherapy drug and the near-infrared photosensitizer, achieves tumor targeting and selectivity, thereby increasing the drug accumulation at the tumor site, improving the therapeutic effect, and reducing toxic side effects. This solves the problems of existing near-infrared fluorescent dyes, which have limited targeting and selectivity and low therapeutic effect.

The invention provides a preparation method of a culture solution for promoting gonad development of pinctada maxima. According to the preparation method of the culture solution for promoting gonad development of the pinctada maxima, Chinese herbal medicine components such as the radix isatidis and the honeysuckle flowers are blended and the proportion is optimized, so that gonad maturation of the pinctada maxima can be directionally stimulated, harmful bacteria in a culture environment can be inhibited, the culture survival rate is remarkably increased, and the double benefits of promoting development and preventing diseases are achieved; the selected Chinese herbal medicines are free of toxic and side effects, free of hormone residues, free of environmental pollution during use, free of drug accumulation in pinctada maxima bodies, easy and convenient to operate, low in cost and extremely high in popularization value. A traditional culture solution formula system is further optimized, efficient application of Chinese herbal medicine ingredients in the field is achieved for the first time, the disease outbreak risk in the breeding process is effectively avoided, and a solid theoretical support and practical reference are provided for the gonad development promoting technology in large-scale breeding of the pinctada maxima.

A preparation method of an albumin-paclitaxel twin drug nanoparticle. The preparation particularly relates to mixing albumin with water to prepare an albumin solution; mixing paclitaxel or a paclitaxel twin drug compound with an organic solvent to obtain a drug solution; and mixing the albumin solution with the drug solution, and performing ultrasonic dispersion, and then rotary evaporation and ultrafiltration to prepare an albumin-binding paclitaxel or albumin-paclitaxel twin drug nanoparticle. Disclosed is a use of the albumin-paclitaxel twin drug nanoparticle. Drug accumulation in tumors can be increased by means of using the special GP60-caveolin-SPARC transport mechanism of albumin, and the anti-tumor effect is good.

The application belongs to the technical field of nano drug loading, and particularly relates to an acid response drug delivery nanoparticle suitable for pancreatic cancer and a preparation method. The polyphenol polymer is a polymer with a biodegradable polyethylene glycol (PEG) polyphenol as a skeleton, and then a metal ion chelation effect is used to load a hydrophobic drug, improved gemcitabine and leflunomide, to form a nanoparticle. The nanoparticle can release the improved gemcitabine and leflunomide in response to a special environment in tumor cells, can regulate mitochondrial metabolism of pancreatic tumor cells, induce cell ferroptosis, and at the same time, the nanoparticle can induce mitochondrial exocytosis to realize deep drug accumulation, regulate an immune-metabolic network of multiple cells in a tumor lesion tissue, relieve an immunosuppressive microenvironment, and inhibit pancreatic tumors.

This invention discloses a nanomedicine and its application in the four-modal synergistic treatment of ER+ breast cancer, encompassing gas therapy, photothermal therapy, photodynamic therapy, and combined therapy, relating to the fields of biotechnology and new medicine. This nanomedicine uses an amphiphilic polymer as a carrier and organic compounds and photosensitizers as drug loading agents. Through the synergistic effects of four modes—photothermal, photodynamic, gas therapy, and combined therapy—it effectively inhibits the growth and metastasis of breast cancer cells. The amphiphilic polymer, based on PHHM-ADT, is modified with hydrogen sulfide gas as a donor, and its amphiphilicity allows for spontaneous assembly into nanoscale hollow, regular spheres. Utilizing the high permeability and retention effect (EPR effect) at the tumor site, it achieves efficient drug accumulation in tumor tissue. The prodrug PSF couples fulvestrant and pabuxiparin via disulfide bonds, and the photosensitizer IR808 integrates photothermal and photodynamic therapy. The synergistic effect of multiple mechanisms of action enhances the therapeutic effect.

The present disclosure relates to a high-drug-loading molecular state simvastatin skin ointment and a preparation process therefor. The ointment comprises simvastatin and a basic matrix composition. The basic matrix composition comprises a basic matrix, a solubilizer, a consistency regulator, a stabilizer, and the like. According to the ointment of the present disclosure, simvastatin is stably present in the basic matrix composition in the form of molecules. Phospholipid and cholesterol, as the solubilizer and the stabilizer, are self-assembled in a non-aqueous solution to form a reverse micelle structure, thereby enhancing the stability of a drug. Meanwhile, the solubility of a weak-polarity drug is increased by means of the reverse micelle system, so that the skin retention amount can be greatly increased when the reverse micelle system is used as a percutaneous administration carrier, thereby enhancing the percutaneous absorption of the drug. The formulation of the present disclosure is easy to prepare, good in storage stability, high in drug loading, high in drug accumulation amount in skin, easy to permeate, and quick to take effect, thereby avoiding side effects caused by oral simvastatin.

This invention relates to the field of biomedical technology, specifically to an antifungal nanoparticle, a combination drug, and its application. The antifungal nanoparticle is prepared by covalently linking the aptamer AU1 to drug-loaded silk fibroin nanoparticles via amide bonds. The mass ratio of the drug-loaded silk fibroin nanoparticles to the aptamer AU1 is 20:0.5~2.0. The antifungal nanoparticles of this invention are prepared by a desolvation method using voriconazole-loaded silk fibroin nanoparticles, and the targeting aptamer AU1 is attached to their surface using a carbodiimide chemical cross-linking method. This allows for specific recognition of Candida albicans, increasing drug accumulation at the infection site. Further combination with methylene blue-mediated photodynamic therapy can disrupt biofilm structures, enhance nanoparticle penetration, achieve synergistic bactericidal activity, and reduce systemic toxicity, providing a novel, highly effective, and low-toxicity treatment strategy for fungal biofilm infections.

The invention relates to a grinding device for pharmacy. The grinding device comprises a supporting base, a tamping rod frame is connected to the supporting base, a grinding tank is arranged on the lower portion of the tamping rod frame, an electric secondary telescopic rod is connected to the upper portion of the tamping rod frame, a grinding block is connected to the telescopic end of the electric secondary telescopic rod, and a driving piece is connected between the tamping rod frame and the grinding tank. The technical scheme of the invention has the beneficial technical effects that the electric secondary telescopic rod is adopted to drive the grinding block to realize lifting, extruding and grinding, so that each medicine raw material can be in uniform contact with the extruding and grinding surface of the grinding block, the problem of non-uniform grinding caused by local accumulation and corner residues of medicines is effectively avoided, and the granularity consistency of final ground products is ensured. The synergistic grinding mode is especially suitable for scenes with high requirements on the fineness of medicine powder in pharmaceutical research and preparation production, high-quality raw materials can be provided for subsequent medicine dissolution, mixing and preparation forming, and the dissolution rate and the medicine effect stability of the medicine are indirectly guaranteed.

The present invention discloses the use of a short-term embolic agent in reducing drug accumulation in the liver, hepatic clearance and / or liver toxicity. The present invention provides the use of a short-term embolic agent in the manufacture of a medical composition for: (a) temporarily embolizing blood vessels supplying the liver; and (b) reducing the accumulation of a drug subsequently or concurrently administered intravenously in the liver. The strategy aims to minimize the exposure of a drug (such as LNP) to the liver by temporarily blocking the blood supply to the liver via the portal vein and / or arteries. The present invention significantly reduces the non-specific accumulation of a drug in the liver by temporarily blocking the portal vein, arterial and / or their branch blood flow, thereby greatly reducing the opportunity for the drug to enter the liver from a hemodynamic root.

This invention discloses the application of GRP94 protein as a drug delivery target in the construction of drug carriers for Parkinson's disease. GRP94 is highly upregulated on the cell membranes of dopaminergic neurons in the substantia nigra of Parkinson's disease cells, while its expression is extremely low on the surface of normal brain cells. The invention also discloses the application of GRP94 as a target in a targeted delivery system for anti-Parkinson's disease drugs. By targeting GRP94, the delivered anti-Parkinson's drug can efficiently penetrate the blood-brain barrier to reach the brain parenchyma, avoiding normal brain cells and specifically targeting dopaminergic neurons in the substantia nigra of Parkinson's disease cells, thus achieving targeted drug delivery for Parkinson's disease. This invention applies GRP94 as a target in the construction of drug carriers for Parkinson's disease and in the preparation of targeted delivery systems for anti-Parkinson's disease drugs. Compared to other target receptors that cross the blood-brain barrier for targeted brain delivery, targeting GRP94 more specifically targets dopaminergic neurons in the substantia nigra, avoiding drug accumulation and neurotoxicity in normal intracranial regions.

The invention belongs to the technical field of medicines, and particularly relates to a glutamine metabolism regulation nano drug delivery system for enhancing pancreatic cancer targeting and penetration as well as a preparation method and application of the glutamine metabolism regulation nano drug delivery system. The metabolism regulation medicine is a glutamine transporter and a metabolic enzyme inhibitor; the nano drug delivery system is formed by self-assembly of a multifunctional block polymer and a drug; the polymer has collagen targeting peptide CBP modification, and can target high-abundance collagenous fibers to realize tumor enrichment; the MMP-7 response peptide can respond to high-concentration MMP-7 and trigger size reduction and deep penetration of the drug delivery system; the responsive drug release element can trigger drug release in a tumor intracellular reduction environment. The constructed nano drug delivery system is high in compatibility and suitable for selective delivery of various metabolic regulation drugs; pancreatic cancer drug accumulation and deep penetration can be remarkably enhanced, non-target tissue leakage is reduced, and accurate drug delivery and metabolism regulation strategy synergism and toxicity reduction are achieved.

This invention discloses a nanoemulsion gel containing Sichuan pepper volatile oil, its preparation method, and its application. The Sichuan pepper volatile oil nanoemulsion gel of this invention comprises a core layer and an encapsulation layer. The core layer is a nanoemulsion loaded with Sichuan pepper volatile oil, and the encapsulation layer is a carboxymethyl chitosan-sodium alginate composite hydrogel. The composite hydrogel forms a three-dimensional network structure through calcium ion cross-linking, encapsulating the Sichuan pepper volatile oil-loaded nanoemulsion within it. This invention prepares Sichuan pepper volatile oil into a nanoemulsion, significantly improving its water solubility and chemical stability, and reducing degradation in the gastrointestinal tract after oral administration. Further encapsulation with the carboxymethyl chitosan-sodium alginate composite hydrogel utilizes the pH sensitivity and colonic enzyme responsiveness of the composite hydrogel to reduce drug release in the stomach and small intestine, allowing the drug to degrade and release upon reaching the colon, thus increasing drug accumulation at sites of colonic inflammation. This solves the problems of poor targeting and low bioavailability of Sichuan pepper volatile oil.

The invention discloses a short-chain cell-penetrating peptide P3, a targeting drug-loaded micelle and application thereof, the sequence of the short-chain cell-penetrating peptide P3 is Trp-Lys-Ala-Ser-Cys (WKASC), and the peptide sequence containing the function covers all derivative peptide sequences which take the five peptide sequences as a skeleton and are connected with other functional amino acids or short peptide sequences at the N end or the C end. The invention can realize efficient recognition and penetration of in vivo / in vitro non-small cell lung cancer cells, and has the characteristics of low cytotoxicity, good biocompatibility, no significant hemolytic toxicity and the like. A targeting delivery system can be constructed by coupling the polymer carrier with a polymer carrier and loading a chemotherapeutic drug (such as adriamycin). The system can effectively overcome biological barriers, improve enrichment of drugs in tumor tissues and intracellular delivery efficiency, significantly inhibit tumor growth, reduce systemic toxicity and side effects, and provide a new strategy for precise treatment of lung cancer.

This invention discloses an injectable hydrogel loaded with 4-octyl itaconic acid, its preparation method, and its applications, belonging to the field of biomedical materials technology. The injectable hydrogel is formed by enzymatic cross-linking of a hyaluronic acid-tyramine complex to create a three-dimensional network, with 4-octyl itaconic acid encapsulated within this network structure. This invention allows for precise implantation of the hydrogel into the intervertebral disc lesion via minimally invasive injection, achieving local high-concentration drug accumulation. The three-dimensional network of the hydrogel serves as a drug reservoir, enabling continuous and controllable release of 4-OI, prolonging the drug's duration of action and achieving long-term therapeutic effects. Simultaneously, the loaded 4-OI specifically activates the Nrf2 / GPX4 antioxidant pathway in nucleus pulposus cells, mechanistically antagonizing ferroptosis and matrix degradation, thus achieving a dual function of mechanical support and biological therapy. It exhibits good biocompatibility and solves the problems of difficult targeted drug delivery, short-lived efficacy, and lack of disease-modifying effects in existing treatments for intervertebral disc degeneration.

The invention relates to the technical field of medical treatment, and discloses a cardiovascular disease inpatient falling risk dynamic assessment system, which comprises a fusion monitoring module, a data calculation module, a basic analysis module and a joint assessment module, and is characterized in that the fusion monitoring module is used for constructing a patient medication data set and a patient physiological feature data set; the data calculation module is used for calculating a drug accumulation influence coefficient and a patient individual sensitivity index, the basic analysis module is used for analyzing a falling risk index of a current patient, and the joint evaluation module is used for judging whether the patient is suitable for independent activities and monitoring an activity state data set of the patient; and calculating an activity risk index, comparing the activity risk index with an activity risk threshold, and feeding back based on a comparison result. According to the system, the risk assessment accuracy and credibility are improved.

The use of a KIF18A inhibitor in the preparation of a drug for treating lung cancer (e.g., non-small cell lung cancer) diseases. It is verified in pharmacological experiments that compound 1 or compound 2 can inhibit the growth of non-small cell lung cancer xenografts. Compared with AMG650, compound 1 or compound 2 has a lower drug exposure which can reduce the potential drug cumulative toxicity. It is shown that compound 1 or compound 2 has significant therapeutic effects on non-small cell lung cancer.

The invention provides a medicine conveying device of a suspension type automatic assembly line, and relates to the technical field of suspension type assembly lines. The medicine conveying device of the suspension type automatic assembly line comprises a U-shaped plate, a limiting mechanism, an elastic mechanism, a semi-annular flow guide plate and a semi-sealing ring, the U-shaped plate is connected to the lower end of a suspension type conveying component and used for clamping infusion bottles, the limiting mechanism is used for fixing and removing the infusion bottles, and the elastic mechanism is arranged at the upper end of the limiting mechanism and used for clamping the semi-annular flow guide plate. The semi-annular flow guide plate is detachably installed at the upper end of the elastic mechanism, the semi-sealing ring is arranged on the inner side of the semi-annular flow guide plate, the semi-annular flow guide plate vertically moves through the elastic mechanism, and the upper end of the semi-annular flow guide plate is an inclined face. The infusion bottle is fixed again through the limiting mechanism, and displacement of the infusion bottle caused by shaking is avoided; the outer side of a bottle opening of the infusion bottle is sealed and clamped by splicing the two semi-annular flow guide plates, so that microorganism breeding caused by liquid medicine gathering is avoided, and meanwhile liquid medicine is guided to be discharged; the elastic mechanism ensures that the semi-annular guide plate does not interfere with the rubber plug gland operation.

The invention provides a regorafenib-entrapped albumin preparation, a pharmaceutical composition and a preparation method and application of the regorafenib-entrapped albumin preparation, the regorafenib-entrapped albumin preparation is prepared from regorafenib into an albumin nano preparation, the solubility of REG is enhanced, side effects are relieved, the biological half-life period is prolonged, long-acting circulation is achieved, and the regorafenib-entrapped albumin preparation has a good application prospect. And the curative effect is enhanced by increasing the tumor tissue drug accumulation amount. In addition, according to the pharmaceutical composition, the regorafenib component is added into the albumin paclitaxel preparation, so that the pharmaceutical composition has the capability of synergistically reprogramming macrophages. Cell experiments prove that the combined use of PTX and REG under certain proportion conditions can enhance the M1 type polarization of macrophages.

The application provides a method for evaluating drug accumulation toxicity based on ex vivo rabbit corneal long-term perfusion, and belongs to the technical field of drug accumulation toxicity evaluation. The method comprises the following steps: preparing a perfusion sample and building a perfusion device; performing continuous perfusion, collecting corneal physiological response data and drug concentration monitoring data in real time; performing denoising processing on the collected original data, and extracting drug accumulation toxicity characteristic parameters; inputting the toxicity characteristic parameters into a drug accumulation toxicity evaluation model based on a convolutional neural network to obtain a corneal toxicity grade under the current perfusion condition; establishing a multi-objective analysis model, solving the model, and obtaining a quantitative evaluation result of drug accumulation toxicity and a safe perfusion threshold; and determining the corneal toxicity risk grade of the drug and the safe use concentration range. The application ensures the reliability of the data through a denoising algorithm and a feature extraction method, realizes accurate toxicity determination by using a neural network, improves the scientificity and efficiency of the evaluation, and provides a precise toxicity evaluation method for animal ophthalmic drug research and development.

The invention relates to a bionic nano delivery platform for brain targeting and photothermal therapy, a preparation method of the bionic nano delivery platform and application of the bionic nano delivery platform in treatment of neurodegenerative diseases. The platform is composed of a drug-loading core and a functionalized shell, wherein the drug-loading core is a cycloastragenol-loaded liposome; the functionalized shell covers the drug loading core and is composed of a microcolloid cell membrane and a near-infrared two-region photo-thermal material dispersed in the microcolloid cell membrane. According to the structure, through cell membrane bionic modification, a platform is endowed with good brain focus targeting, efficient immune escape ability and a remarkable drug enrichment effect, and collaborative delivery and controlled release of cycloastragenol and a photo-thermal material can be achieved. The platform and the system have the comprehensive advantages of being accurate in brain targeting, remarkable in treatment synergistic effect and good in biocompatibility, and have wide clinical application prospects in the field of targeted therapy of neurodegenerative diseases.

This invention relates to the fields of biomedical engineering and drug delivery technology, specifically disclosing a novel targeted drug delivery system based on rosehip extracellular vesicles, comprising: preparing rosehip-derived extracellular vesicles; preparing drug-loaded vesicles; and preparing targeted modified drug-loaded vesicles. This invention utilizes the specific downregulation of stem cell-related pathways by rosehip components, while simultaneously leveraging doxorubicin to kill conventional tumor cells, forming a complementary therapeutic mechanism to fundamentally reduce the risk of tumor recurrence. The phenylboronic acid group of DSPE-PEG-PBA specifically recognizes sialic acid overexpressed on the surface of tumor cells, significantly increasing drug accumulation in tumor tissues while reducing distribution in normal tissues. By leveraging the natural biocompatibility and low immunogenicity of RHNVs, combined with the long-circulating properties of the PEG chain, systemic toxicity is minimized while ensuring delivery efficiency, particularly reducing the cardiotoxicity and bone marrow suppression of doxorubicin.

The invention relates to the technical field of medical control, and discloses an anesthesia assisting method for promoting postoperative rapid recovery, which comprises the following steps: constructing a basic pharmacokinetic model for a selected anesthetic; intraoperative multi-modal data of a patient are collected in real time; calculating a temperature-metabolism correction coefficient based on the thermodynamic data, and calculating a volume-dilution correction coefficient based on the hemodynamic data; correcting the basic plasma clearance rate in real time by using the temperature-metabolism correction coefficient, and correcting the basic central ventricle distribution volume in real time by using the volume-dilution correction coefficient; the corrected plasma clearance rate and the corrected central ventricle distribution volume are substituted into the basic pharmacokinetic model, and the medicine infusion rate needed for maintaining the preset target concentration is calculated. According to the method, the parameters of the pharmacokinetic model are dynamically corrected according to the real-time thermal dynamics and hemodynamics data, medicine accumulation is effectively avoided, and the postoperative awakening time is shortened.

The invention provides an intestinal flora composition for preventing or treating osteoporosis and application thereof, and relates to the technical field of biology. According to the invention, causal association analysis is carried out on whole genome heritable variation data and intestinal flora data of East Asian population through a Mendel randomization method, and the intestinal flora for preventing or treating osteoporosis is screened out; comprising acid amide bacteria enterobacter, bacillus haulis, kiwifruit bacteria, archaea extensa, streptococcus ricini and lysobacter pitermannii, and an accurate microbial intervention target is provided for prevention and intervention of osteoporosis. The intervention mode based on microbiomics has the advantages of noninvasiveness, high safety, good tolerance and the like, can be used for a long time, has no drug accumulation risk, and is especially suitable for early prevention and chronic management scenes of osteoporosis.

This invention relates to a brain-targeting nanomedicine formulation for glioblastoma and its preparation method, belonging to the field of pharmaceutical technology. The formulation comprises an active pharmaceutical ingredient, an amphiphilic block copolymer carrier, a covalently bonded brain-targeting ligand, and a stabilizer. The preparation method includes: chemically coupling the targeting ligand to the carrier material; self-assembling the drug, modified carrier, and stabilizer into nanoparticles using a nanoprecipitation method; and obtaining the final product through membrane extrusion granulation, purification, and lyophilization. The resulting nanoparticles have uniform particle size, high drug loading, and good stability, and can simultaneously achieve efficient crossing of the blood-brain barrier and specific targeting of glioma cells. In vitro and in vivo experiments show that this formulation can significantly improve drug accumulation at brain tumor sites, inhibit tumor growth, and prolong the survival of model animals. Furthermore, the preparation process is controllable and easily scaled up.

The invention discloses a ginseng exosome coated gold nano-cluster compound and application thereof in preparation of a medicine for treating lung cancer, and belongs to the field of biological medicine and nano-medicine preparations. The compound takes a gold nano-cluster loaded with siCD47 as an inner core and a ginseng exosome as a shell. The nano system is assembled by adopting a one-step micro-fluidic technology, the process is simple and convenient, and the repeatability is high. The gold nanoclusters in the core of the compound can effectively protect and deliver siCD47, efficiently silence CD47 genes of tumor cells and block immune escape signals; the ginseng exosome shell realizes the specific enrichment of the drug at the tumor site by utilizing the targeting of the natural lung, and can promote the phenotype polarization of macrophages to M1 and reprogram the tumor immune microenvironment. Through a synergistic immunotherapy mechanism of de-shielding and reactivation, the compound shows a remarkable inhibition effect on drug-resistant lung cancer in vivo and in vitro, is high in biological safety, and provides a new strategy and preparation for treatment of lung cancer, especially drug-resistant lung cancer.